Acute Human Study: StimRouter for Peripheral Nerve Stimulation of Discrete Peripheral Nerves (StimRouter)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00665132 |
|
Recruitment Status :
Completed
First Posted : April 23, 2008
Results First Posted : June 6, 2016
Last Update Posted : June 6, 2016
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Unilateral Carpal Tunnel Syndrome | Device: StimRouter System | Phase 1 Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 10 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Acute Human Study: StimRouter for Peripheral Nerve Stimulation of Discrete Peripheral Nerves |
| Study Start Date : | April 2008 |
| Actual Primary Completion Date : | December 2008 |
| Actual Study Completion Date : | December 2008 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: StimRouter (SR) for CTS
Percutaneous implantation of StimRouter System
|
Device: StimRouter System
Implanted with StimRouter System receive 6 hours (or less if not tolerated by the Subject)of electrical therapeutic stimulation each day for a total of 5 days (from start of successful programming) |
- Implant Success [ Time Frame: at device implantation procedure ]Success of device implantation was defined as uncomplicated minimally-invasive implantation of the StimRouter Lead near the targeted peripheral median nerve, resulting in production of desired paresthesias in the sensory distribution of the median nerve when active peripheral nerve stimulation was applied. This outcome parameter was intended to serve as an indication that the lead and electrode stimulating positions could be correctly placed while still maintaining the minimal invasiveness of the procedure. Fluoroscopic imaging was used to document positioning of the StimRouter Lead and, by applying stimulation from a commercially available Dakmed External Pulse Generator (EPG) to the StimRouter Lead, desired paresthesia response was confirmed.
- Patent Satisfaction [ Time Frame: Day 5 after final stimulation ]Numerical rating scale (NRS) of 0-10 where 0 = not satisfied and 10 = very satisfied
- Percent of Participants Reporting Pain Change From Baseline to Day 5 [ Time Frame: Day 5 ]Brief Pain Inventory (BPI) questions 14 and 15 were used to measure pain change after 5 days use of StimRouter System. In the BPI, an 11-point numerical rating scale (NRS) is used to rate pain intensity, where zero (0) indicates ''no pain'' and 10 indicates ''pain as bad as you can imagine.'' At enrollment, participants circled the number that best described how much baseline pain they had 'on average' (BPI #14). After enrollment and during the study, patients circled the one number that best described how much pain they had at that time 'right now' (BPI #15). The percent of participants with change from Baseline to Day 5 was calculated.
- Mean Change in Pain Achieved by Participants Who Reported Pain Change From Baseline to Day 5 [ Time Frame: Day 5 after final stimulation ]Using Brief Pain Inventory questions 14 and 15, those 9 subjects who had pain change from Baseline to Day 5 were analyzed to determine change in pain for the overall group. In the BPI, an 11-point NRS is used to rate pain intensity, with a 0 for ''no pain'' and a 10 for ''pain as bad as you can imagine.'' At Baseline, patients circled the number that best described how much baseline pain they had 'on average' (BPI #14). During the study, patients circled the one number that best described how much pain they had at the time 'right now' (BPI #15).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 18 years of age or older
- Chronic peripheral pain persisting for greater than or equal to 3 months diagnosed previously as a mononeuropathy of the median nerve at the level of the carpal tunnel (i.e., diagnosed CTS)
- Average chronic pain level greater than or equal to 5/10 [on 0-10 numeric rating scale (NRS) (BPI#14)], where such pain is attributed to injury, irritation, or entrapment of the median nerve at the level of the carpal tunnel (i.e., diagnosed CTS)
- Failure of a single prior carpal tunnel release surgery to provide relief, where such failed surgery was performed greater than or equal to study entry
- Able to tolerate stimulation (TENS)
- Temporary pain relief is achieved by local anesthetic block of the target median nerve suspected to be the source of chronic pain symptoms
- Ability to give informed consent and understand study requirements
- Ability to quantify pain using a 0-10 numeric rating scale [A screening tool will be used to ensure that subjects can rate 3 common pain scenarios (mosquito bite, stubbed toe and broken bone) on a 0-10 NRS relative to each other, with mosquito bite < stubbed toe < broken bone]
- Willing and able to understand and comply with all study-related procedures during the course of the study
- Motivated to maintain an accurate diary for the study duration
Exclusion Criteria:
- Metal implants in the forearm
- Active infection
- Active or existing skin disorder or irritation which, at the physician's discretion, contraindications use of skin gel electrodes
- Allodynia
- Regular use of antiplatelet medications [e.g., aspirin, ticlopidine (Ticlid), clopidogrel (Plavix), tirofiban (Aggrastat), and eptifibatide (Integrilin)]
- Anticoagulated (taking warfarin or heparin, including fractionated heparin) or has a bleeding disorder
- Cardiac pacemaker
- Implanted neurostimulator (e.g., spinal cord, deep brain, vagus nerve stimulator) or implanted pump or infusion device
- History of cardiac arrhythmia with homodynamic instability
- Untreated drug habituation or dependence
- Psychologically or medically unstable
- Uncontrolled seizures (averaging > 2 seizures per month)
- Pregnant or plan on becoming pregnant or breastfeeding during the study period
- Currently require, or likely to require, diathermy and/or MRI during the study duration
- History of adverse reactions to local anesthetic (e.g., lidocaine)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00665132
| United States, West Virginia | |
| The Center for Pain Relief | |
| Charleston, West Virginia, United States, 25301 | |
| Study Director: | Evan L. Rosenfeld, MD, JD | Bioness Inc |
| Responsible Party: | Bioness Inc |
| ClinicalTrials.gov Identifier: | NCT00665132 |
| Other Study ID Numbers: |
CP-STMR07-001-Rev A.1 |
| First Posted: | April 23, 2008 Key Record Dates |
| Results First Posted: | June 6, 2016 |
| Last Update Posted: | June 6, 2016 |
| Last Verified: | May 2016 |
|
wrist hand pain failed CTR carpal tunnel syndrome |
CTS CTR carpel tunnel release Peripheral nerve Median nerve |
|
Carpal Tunnel Syndrome Median Neuropathy Mononeuropathies Peripheral Nervous System Diseases Neuromuscular Diseases |
Nervous System Diseases Nerve Compression Syndromes Cumulative Trauma Disorders Sprains and Strains Wounds and Injuries |

